Loading the session
Loading the session
Loading instrument
$486.29
+1.63%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $478.48 on 4 Nov 2026: 0.8% below the 52-week high of $482.48 (4 Nov 2026) and 53.2% above the low of $312.39 (11 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +18.8% (SPY −1.6%, XLV +13.5%). 3 months: +17.3% (SPY −0.4%, XLV +15.5%). 1 year: +61.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AMGN, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $478.48 was 13.5% above its 50-day average ($421.56) and 27.0% above its 200-day average ($376.86). It has closed above the 200-day for 108 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 13 Nov 2025, 244 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 73.4 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
$2.52 a share, payable 11 Dec 2026; unchanged from the previous payment (ex-date 21 Aug 2026).
Corporate actions record · as of 5 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
September 8, 2026
−10.08%February 4, 2026
+8.15%May 3, 2024
+11.82%